Prospector
Profile
07.1159
|
| |
| Stem Cell Therapy International, Inc. |
NAICS |
541710 |
| 2203 North Lois Avenue, 9th Floor
Tampa, FL 33607 |
Description |
Biotechnology |
| (813) 600-4088 |
Employees |
2 |
| http://www.scticorp.com/ |
Revenue |
(mil) |
0.3450 |
| |
Income |
(mil) |
-0.6570 |
| |
Assets |
(mil) |
0.1380 |
| |
Liability |
(mil) |
0.6320 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Aidman Piser & Company PA raised doubts about the ability of Stem Cell Therapy International, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company has experienced recurring losses from operations since its inception and at March 31, 2007, has a working capital deficit of $551,175 and an accumulated deficit from operations of $1,189,448.
|
| |
|
Intellectual Property:
The Company holds rights to 26 patents registered in the Ukraine. It intends to apply for patents based on the technologies behind these 26 Ukrainian patents in other countries, including the United States. [SEC Filing 10-KSB 07-13-07]
|
| |
|
Description:
The Company engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services.
|
| |
|
Officers:
Calvin C. Cao (Chair & CEO); Daniel J. Sullivan (CFO); Lixian Jiang (COO)
|
| |
|
Auditor:
Aidman Piser & Company PA
|
| |
|
Securities:
Common Stock-Symbol SCII.OB; OTC BB;
34,750,889 common shares outstanding as of June 20, 2007.
|
| |
| |
| |
| return to main page |
